Singapore markets close in 1 hour 25 minutes

Prometheus Biosciences, Inc. (RXDX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
95.80+59.74 (+165.67%)
At close: 04:00PM EST
101.47 +5.67 (+5.92%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close36.06
Bid0.00 x 1200
Ask0.00 x 800
Day's range94.87 - 111.99
52-week range21.50 - 111.99
Avg. volume597,709
Market cap4.018B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.78
Earnings date13 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est64.18
  • Motley Fool

    These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday

    Stock markets prepared to continue their downward trend on Wednesday, as early morning moves in futures markets indicated further declines after two losing sessions on Monday and Tuesday. The Nasdaq Composite (NASDAQINDEX: ^IXIC) looked poised to suffer the most significant declines, with futures contracts falling more than 1% in premarket trading. MongoDB (NASDAQ: MDB) rose sharply after the software-as-a-service (SaaS) company reported solid financial results late Tuesday, but the biggest pop came for Prometheus Biosciences (NASDAQ: RXDX).

  • Motley Fool

    Why Shares of Prometheus Biosciences Slumped This Week

    Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.

  • Zacks

    Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates

    Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?